Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | PDE6D | O43924 | 3/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.49 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.49 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.49 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.49 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3892502 | 0.84 | ALDH1A1 (0.61) | ALDH1A1NPSR1POLBMEN1KMT2A | |
| SCHEMBL7168715 | 0.83 | HTR3A (0.81) | HTR3AALDH1A1 | |
| SCHEMBL15568031 | 0.82 | HTR3A (0.66) | HTR3AALDH1A1TP53MEN1KMT2A | |
| SCHEMBL15569479 | 0.79 | HTR3A (0.58) | HTR3AALDH1A1PDE6DNPSR1POLB | |
| SCHEMBL4435849 | 0.79 | HTR3A (0.67) | HTR3AALDH1A1SMN1; SMN2 | |
| SCHEMBL15474498 | 0.78 | PDE6D (0.66) | HTR3APDE6DMEN1KMT2A | |
| SCHEMBL10967129 | 0.77 | HTR3A (0.71) | HTR3A | |
| SCHEMBL7341277 | 0.77 | HTR3A (0.75) | HTR3AALDH1A1MEN1KMT2A | |
| SCHEMBL15568472 | 0.75 | HTR3A (0.57) | HTR3AALDH1A1PDE6DMEN1KMT2A | |
| Lerisetron SCHEMBL141124 | 0.74 | HTR3A (1.00) | HTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1670775-A4 | PIPERAZINE SUBTITUTED COMPOUNDS USED AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD (CA) | 2009-04-22 | — | — | EP | claimed |
| US-7186726-B2 | Preferentially substituted calcium channel blockers | NEUROMED PHARMACEUTICALS LTD. (CA) | 2007-03-06 | — | — | US | claimed |
| JP-2007504174-A | — | — | 2007-03-01 | — | — | JP | claimed |
| EP-1670775-A1 | PIPERAZINE SUBTITUTED COMPOUNDS USED AS CALCIUM CHANNEL BLOCKERS | Neuromed Pharmaceuticals, Ltd. (CA) | 2006-06-21 | — | — | EP | claimed |
| WO-2005021523-A1 | PIPERAZINE SUBSTITUTED COMPOUNDS USED AS CALCIUM CHANNEL BLOCKERS | NEUROMED TECHNOLOGIES, INC. (CA) | 2005-03-10 | — | — | WO | claimed |
| US-20040147529-A1 | Preferentially substituted calcium channel blockers | ZALICUS PHARMACEUTICALS LTD. (CA) | 2004-07-29 | — | — | US | claimed |
| US-20080300262-A1 | Combination Therapy for Relief of Pain | ZALICUS PHARMACEUTICALS LTD. (CA) | 2008-12-04 | — | — | US | disclosed |
| EP-1871372-A1 | COMBINATION THERAPY COMPRISING AN N-TYPE CALCIUM CHANNEL BLOCKER FOR THE ALLEVIATION OF PAIN | Neuromed Pharmaceuticals, Ltd. (CA) | 2008-01-02 | — | — | EP | disclosed |
| US-7186726-B2 | Preferentially substituted calcium channel blockers | NEUROMED PHARMACEUTICALS LTD. (CA) | 2007-03-06 | — | — | US | disclosed |
| WO-2006105670-A1 | COMBINATION THERAPY COMPRISING AN N-TYPE CALCIUM CHANNEL BLOCKER FOR THE ALLEVIATION OF PAIN | NEUROMED PHARMACEUTICALS LTD. (CA) | 2006-10-12 | — | — | WO | disclosed |
| US-20040147529-A1 | Preferentially substituted calcium channel blockers | ZALICUS PHARMACEUTICALS LTD. (CA) | 2004-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147529-A1 | Preferentially substituted calcium channel blockers | CACNA1B, CACNA1C, CACNA1D | HTR3A 429/4885ALDH1A1 3720/4885TP53 4529/4885 |
| US-20080300262-A1 | Combination Therapy for Relief of Pain | CACNA1B, TRPV1, ORAI1 | HTR3A 398/4885ALDH1A1 4513/4885TP53 4770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.